Under the agreement, Qilu will be responsible for the development, regulatory registration and supply of QL2107, while Cipla USA Inc. will handle the commercialisation of the product in the defined US territory, leveraging its commercial presence.
The companies said the collaboration is aimed at addressing the growing burden of cancer and improving access to advanced biologic therapies.
ALSO READ | Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix
Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio. By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.”
Marc Falkin, Chief Executive Officer, Cipla North America, said, “This collaboration is aligned with our strategy to expand our biosimilar portfolio in the coming fiscal years, and we are excited to add QL2107 with Qilu, who have been great partners.
With our established commercial capabilities, we are well-positioned to successfully launch QL2107, subject to regulatory approval, and help ensure it reaches patients in need while lowering the cost of treatment.”
ALSO READ | Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm
Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, “We are pleased to establish this partnership with Cipla for QL2107. Qilu boasts a robust and growing biosimilar product pipeline.
By combining our R&D and manufacturing strengths with Cipla’s US commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to US patients.”
Shares of Cipla Ltd ended at ₹1,389.00, down by ₹24.15, or 1.71%, on the BSE.
ALSO READ | Cipla Pharma license cancellation: FDA withdraws order after Bombay HC raps it for going ‘overboard’
